Neuropeptide Y gene promoter -399T/C polymorphism increases risk of ischemic stroke
Neuropeptide Y gene promoter -399T/C polymorphism increases risk of ischemic stroke
Background: Several genetic factors underlying ischemic stroke have been identified. Variants of Neuropeptide Y (NPY), whose product plays diverse roles in modulating physiological functions, have been associated with an increased risk of ischemic stroke in South Korean individuals. Aims: We explored the association between a polymorphism in the NPY gene promoter at position -399 and the risk of ischemic stroke in Han Chinese. Study Design: Case-control study. Methods: The polymorphism -399T/C in the promoter of NPY was analysed in 500 patients with ischemic stroke and 500 healthy individuals by amplification and sequencing of this region. Non-conditional logistic regression was used to analyse association between genotypes and the risk of ischemic stroke. Results: Genotype and allele frequencies differed significantly between the ischemic stroke and control groups (P0.05). Conclusion: The -399T/C polymorphism of the NPY gene is associated with ischemic stroke in Han Chinese individuals, and the CC genotype may be a risk factor for ischemic stroke.
___
- 1. Feigin VL. Stroke epidemiology in the developing world. Lancet 2001;365:2160-1. [CrossRef]
- 2. Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med 2011;17:1391-401. [CrossRef]
- 3. Rodriguez-Hernández A, Josephson AS, Langer D, Lawton MT. Bypass for the prevention of ischemic stroke. World Neurosurg 2011;76:S72-9. [CrossRef]
- 4. Flossmann E, Sehulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-27. [CrossRef]
- 5. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke 2003;34:1364-9. [CrossRef]
- 6. Meschia JF, Worrall BB, Rich SS. Genetic susceptibility to ischemic stroke. Nat Rev Neurol 2011;7:369-78. [CrossRef]
- 7. Lundberg JM, Terenius L, Hökfelt T, Martling CR, Tatemoto K, Mutt V, et al. Neuropeptide Y (NPY) like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 1982;116:477-80. [CrossRef]
- 8. Walker P, Grouzmann E, Burnier M, Waeber B. The role of neuropeptide Y in cardiovaseular regulation. Trends Pharmacol Sci 1991;12:111-5. [CrossRef]
- 9. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 1994;50:259-65. [CrossRef]
- 10. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998;83:187-95. [CrossRef]
- 11. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, et al. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004;22:2398-9. [CrossRef]
- 12. Itokawa M, Arai M, Kato S, Ogata Y, Furukawa A, Haga S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosei Lett 2003;347:202-4. [CrossRef]
- 13. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, et al. Neuropeptide Y Gene polymorphisms Confer Risk of Early-Onset Atherosclerosis. PLoS Genet 2009;5:e1000318. [CrossRef]
- 14. Kharlamov EA, Kharlamov A, Kelly KM. Changes in neuropeptide Y protein expression following photothrombotic brain infarction and epileptogenesis. Brain Res 2007;1127:151-62. [CrossRef]
- 15. Lee C, Kong M. An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke. Stroke 2007;38:2663-9. [CrossRef]
- 16. Buckland PR, Hoogendoorn B, Guy CA, Coleman SL, Smith SK, Buxbaum JD, et al. A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity. Biochim Biophys Acta 2004;1690:238-49.
- 17. Kim NS, Oh SM, Ko MM, Cha MH, Kang BR, Bang OS. Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke. Clin Biochem 2009;42:1699- 704. [CrossRef]
- 18. Yu JT, Yu NN, Gao SS, Song JH, Ma T, Wang ND, et al. Neuropeptide Y polymorphisms and ischemic stroke in Chinese population. Clin Chim Acta 2010;411:242-5. [CrossRef]
- 19. Montaner J, Mendioroz M, Delgado P, García-Berrocoso T, Giralt D, Merino C, et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteomics 2012;75:4758-65. [CrossRef]
- 20. Chen SH, Cheung RT. Peripheral and central administration of neuropeptide Y in a rat middle cerebral artery occlusion stroke model reduces cerebral blood flow and increases infarct volume. Brain Res 2002;927:138-43. [CrossRef]
- 21. Mustacchi P. Risk factors in stroke. West J Med 1985;143:186-92.